
1. sci rep. 2016 dec 6;6:38313. doi: 10.1038/srep38313.

limited hiv-1 reactivation resting cd4+ cells aviremic patients under
protease inhibitors.

kumar a(1), abbas w(1), bouchat s(2), gatot js(2), pasquereau s(1), kabeya k(3), 
clumeck n(3), de wit s(3), van lint c(2), herbein g(1).

author information: 
(1)department virology, pathogens &inflammation laboratory, university of
franche-comté, comue bourgogne franche-comté university, upres ea4266, sfr fed
4234, chru besançon, france.
(2)laboratory molecular virology, ibmm, université libre de bruxelles (ulb),
gosselies, belgium.
(3)department infectious diseases, chu st-pierre, ulb, bruxelles, belgium.

a latent viral reservoir resides resting cd4+ cells represents major 
barrier eradication hiv infection. test impact hiv protease
inhibitor (pi) based combination anti-retroviral therapy (cart) over
nonnucleoside reverse transcriptase inhibitor (nnrti)-based cart hiv-1
reactivation integration resting cd4+ cells. prospective
cohort study patients chronic hiv-1 infection treated conventional
cart undetectable viremia. performed seven-year study 47 patients
with chronic hiv-infection treated cart regimens undetectable
plasma hiv-1 rna levels least 1 year. 47 patients treated with
cart, 24 treated pi-based regimen 23 nnrti-based regimen
as recent treatment one year. evaluated hiv-1
reservoir using reactivation assay integrated hiv-1 dna, respectively, in
resting cd4+ cells. resting cd4+ cells isolated pi-treated patients
compared nnrti-treated patients showed limited hiv-1 reactivation upon
t-cell stimulation (p = 0·024) lower level hiv-1 integration
(p = 0·024). study indicates pi-based cart could efficient 
nnrti-based cart limiting hiv-1 reactivation aviremic chronically infected
patients.

doi: 10.1038/srep38313 
pmcid: pmc5138822
pmid: 27922055  [indexed medline]

